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The neuron-astrocyte synaptic complex is a funda-
mental operational unit of the nervous system. Astro-
glia regulate synaptic glutamate, via neurotransmitter
transport by GLT1/EAAT2. Astroglial mechanisms
underlying this essential neuron-glial communication
are not known. We now show that presynaptic termi-
nals regulate astroglial synaptic functions, GLT1/
EAAT2, via kappa B-motif binding phosphoprotein
(KBBP), the mouse homolog of human heteroge-
neous nuclear ribonucleoprotein K (hnRNP K), which
binds the GLT1/EAAT2 promoter. Neuron-stimulated
KBBP is required for GLT1/EAAT2 transcriptional
activation and is responsible for astroglial alterations
in neural injury. Denervation of neuron-astrocyte
signaling by corticospinal tract transection, ricin-
induced motor neuron death, or neurodegeneration
in amyotrophic lateral sclerosis all result in reduced
astroglial KBBP expression and transcriptional
dysfunction of astroglial transporter expression.
Presynaptic elements dynamically coordinate normal
astroglial function and also provide a fundamental
signaling mechanism by which altered neuronal
function and injury leads to dysregulated astroglia
in CNS disease.
INTRODUCTION
The core elements of the central nervous system (CNS) func-
tional unit include presynaptic axons, postsynaptic dendrites,
along with the perisynaptic astroglia which ensheathe the vast
majority of all synapses. Astroglia play a vital and active role in
synaptic transmission (Halassa et al., 2007), by regulating extra-
cellular K+ concentration, by releasing gliotransmitters, and by
modulating glutamate receptor (GluR) activation through gluta-
mate transporter (GluT)-mediated control of synaptic and
extra-synaptic glutamate clearance (Huang and Bergles, 2004).
The astroglial specific plasma membrane glutamate transporter
subtype GLT1 and its human homology, EAAT2 are the dominant880 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.functional/physiologically active transporter in the CNS (Danbolt,
2001; Regan et al., 2007; Rothstein et al., 1994b; Tanaka, 1997).
GLT1/EAAT2 is typically concentrated in perisynaptic mem-
branes (Chaudhry et al., 1995; Danbolt, 2001). GluTs directly
contend with GluRs for glutamate, modulating the intensity and
duration of postsynaptic activation and preventing the interfer-
ence (‘‘spillover’’ or ‘‘spillout’’) of neighboring synapses (Arnth-
Jensen et al., 2002; Huang and Bergles, 2004). Importantly,
astroglial GluTs also prevent accumulation of extracellular gluta-
mate and subsequent over-stimulation of GluRs, thus preventing
possible excitotoxic neuronal death (Rothstein et al., 1996; Ta-
naka, 1997). Experimental disruption of this astroglial function
is neurotoxic and promotes neurodegeneration (Rothstein
et al., 1996). In neurological diseases, the neuron-astroglia
synaptic unit is often disrupted, as reflected by severe loss of
synaptic astroglial GluTs in postmortem human tissue and
rodent models of neurodegeneration (Lauriat et al., 2007;
Lievens et al., 2001; Rothstein et al., 1992).
Despite of the importance of astroglial GluTs in synaptic func-
tion, the normal molecular regulation of the neuron-astrocyte
functional unit is not known. Induction of astroglial GluT expres-
sion occurs in parallel with synapse maturation in early postnatal
development (Furuta et al., 1997). Multiple in vitro studies of
mixed neuron glial cultures suggested that unknown neuronal
secreted factors, added glutamate and/or growth factors can
induce expression of astroglial glutamate transporters GLT1
and GLAST (Munir et al., 2000; Schlag et al., 1998; Swanson
et al., 1997; Zelenaia et al., 2000) or regulate its cytoplasmic clus-
tering (Nakagawa et al., 2008; Zhou and Sutherland, 2004), but
downstream molecular mechanisms have not yet explored. In
vivo studies demonstrate that alteration of sensory activity by
whisker stimulation induces changes in astroglial synaptic
coverage and expression levels of astroglial GluTs, suggesting
that neuronal activity could be linked to astroglial GluTs genomic
regulation (Genoud et al., 2006). With the recent identification of
the GLT1/EAAT2 promoter (Su et al., 2003), it became possible
to evaluate GluT transcriptional regulation and the contribution
of synaptic elements to this astrocytic perisynaptic protein. In
this study, we have identified the transcriptional mechanisms
that underlie normal neuronal/synaptic regulation of astroglial
GLT1/EAAT2 and how in vivo disruption of this astroglial
pathway may be common to subacute and chronic neuronal
disease.
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Axons Are Sufficient and Necessary for Transcriptional
Activation of Astroglial GLT1
A microfluidic culture platform (MCP; Park et al., 2006; Figure 1A)
was used to develop a neuron and astrocyte coculture system in
which only axons penetrate and establish contact with astro-
cytes, thereby providing a system to study the role of neuronal
processes on GLT1 activation at a single axon/astrocyte resolu-
tion. High-density neurons (1–33 106/ml) were first plated on the
right side of the MCP. GDNF (10 ng/ml) was added to the left side
of the MCP to stimulate axon outgrowth 24 hr after seeding of
neurons. Extensive neuronal processes grew through channels
connecting both sides of MCP 3–5 days after adding GDNF
(Figures 1A and 1B). A representative magnified image of axon
and astrocyte is shown in Figure 1B. More than 90% of neuronal
processes growing through the channels are axons, as
confirmed by unique growth cone morphology, immunoreac-
tivity for the growth cone marker 2G13 (Figure 1A), and for syn-
apsin-I (see Figure S1A available online) and immunonegative
for MAP2 (data not shown). The solution exchange between
both sides of the MCP is minimal (Park et al., 2006), as no DiI
and DiO double-labeled astrocytes were observed in each side
of the MCP (Figure S1B) nor was there leakage of 3H-glutamate
between chambers (data not shown). To establish neuron astro-
cyte coculture in the MCP, GDNF was removed when neuronal
processes were still inside the connecting channel, and astro-
cytes were plated into the left chamber. As shown in Figures
1B and 1C, axon bundles, visualized by bIII-tubulin staining,
passed through the channel, entering the astrocyte side of
MCP. Intensity of GLT1 immunostaining (10990 ± 791, arbitrary
units) in astrocytes with the presence of axons was significantly
increased 230% (Figure 1D) compared to that in astrocytes
alone chamber (4781 ± 385), indicating that axons are sufficient
to induce GLT1 activation. Axonal activation of GLT1 expression
is apparently axon number/length dependent, as the intensity of
GLT1 staining (12350 ± 732) in platforms with more axons (indi-
cated by the total length, 7,500–18,889 mm/mm2) is significantly
higher than that (7409 ± 872) in platforms with fewer axons
(3700–7500 mm/mm2; Figures 1C and 1D). In this model para-
digm, the vast majority of GLT1 activation was only seen with
astrocytes contacted by axons (white arrows in Figures 1B and
1C). Highest GLT1 intensity was found in all astrocytes with
axon contact. Only occasional astrocytes, with no obvious direct
axon/terminal contacts, were also GLT1 activated (yellow arrow
in Figure 1C). Subsequent treatment of cultured astrocytes with
differential neuronal components, i.e., neuronal supernatant
(NS), neuronal membrane (NM), or neuron conditional medium
(NCM) were all sufficient to increase GLT1 expression, to a similar
level (Figures S1C and S1D). These results would suggest that
presynaptic interactions with astroglia via direct contact might
activate transcriptional pathways in astroglia.
To study molecular modulation of astroglial synaptic-relevant
pathways, we utilized BAC GLT1 eGFP promoter reporter mice
(Regan et al., 2007), which allow spatial and temporal in situ
monitoring of single astrocyte GLT1 promoter activity by fluores-
cence reporter intensity. The expression of the reporter corre-
lates with endogenous GLT1 promoter activation, proteinexpression, and functional activity (Regan et al., 2007). To
monitor dynamic changes of the GLT1 promoter to axon stimu-
lation, astrocytes derived from this mouse were added on the left
side of MCP after culturing neurons for 3–5 days, prior to entry of
axons into the astroglial chamber. Time-lapse images were
collected from 24 to 112 hr after coculture (Figure 1E). Intensity
of eGFP fluorescence, the indicator of GLT1 genomic promoter
activity, in single astrocytes, was detected and represented by
pseudocolor (Figure 1E). In the absence of axons, no GLT1
appreciable gene activation was observed. Dramatic increase
of eGFP intensity was observed (from 2846 ± 682 to 10860 ±
941) within 48 hr after axons approach and/or make contact
with the astroglia (24–68 hr; Figure 1G). The dependence of the
axon-astrocyte interaction was validated by the decrease in as-
trocytic eGFP expression (68–112 hr), following kainate-induced
(200 mM; added to neuronal side) neural injury and subsequent
axonal degeneration (Figures 1E and 1F). In contrast, eGFP
intensity from MCP without application of kainite only decreased
slightly from 68 to 112 hr (Figure 1G). Axon-dependent eGFP
intensity changes, quantified from these time-lapse images,
clearly indicate that axons induced transcriptional activation of
GLT1. GLT1 mRNA levels were also increased after directly add-
ing neurons to astrocyte cultures (Figure S1E), providing addi-
tional evidence that synaptic interaction with astroglia induces
transcription activation of GLT1.
We further investigated whether glutamate receptor (GluR)-
mediated neuron-astroglial signaling is involved in neuron-
dependent GLT1 activation. P8 rat spinal cord organotypic slice
cultures, a system faithfully mimicking the in vivo environment
(Rothstein et al., 1993), were used to investigate altered
neuron-astrocyte communication on GLT1 activation. As spinal
cord slices are usually 350 mm in thickness, relatively higher
concentrations of pharmacological inhibitors were used in
experiments. GLT1 expression levels in slice cultures were
reduced in a dose-dependent manner following tetrodotoxin
(TTX) treatment (Figures 2A and 2B), suggesting that Na+
channel-mediated synaptic transmission facilitates GLT1 activa-
tion in astrocytes. In addition, treatment of slice cultures with ion-
otropic or metabotropic GluR antagonist cocktails also resulted
in a dose-dependent decrease of GLT1 expression (Figures 2A,
2B, 2E, and 2F). Inhibition of astroglial iGluRs in astrocytes in
MCP also leads to decrease of axon-induced GLT1 expression
(Figures S2A and S2B). Subsequent treatment of slices with indi-
vidual glutamate receptor antagonists revealed that AMPA
(antagonist CNQX) and mGluR 1/5 (antagonist m196) are
involved in the neuron-dependent GLT1 activation (Figures 2C,
2D, 2G, and 2H). NMDA antagonist MK801 had little effect,
although high-dose APV was inhibitory (Figures 2C and 2D).
Overall, mGluR1/5 antagonists alone or in combination ap-
peared to have the greatest effect on GLT1 expression in the
slice culture paradigm (Figures 2E, 2F, 2G, and 2H). GluRs are
expressed on pre- and postsynaptic neurons as well as astro-
cytes, thus, inhibition of GluRs results in inhibition of synaptic
transmission from neuron-to-neuron and neuron-to-astrocyte.
The block of GLT1 activation by inhibition of neurotransmitter
release (TTX) and by the GluR receptor antagonists suggests
that synaptic activity is a strong component of presynaptic-
based activation of astroglial GLT1.Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 881
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Presynaptic Regulation of AstrocytesFigure 1. Axon-Dependent Transcriptional Activation of GLT1 Promoter and GLT1 Protein Expression on a Microfluidic Culture Platform
(MCP)
(A) Diagram of an astrocyte neuron coculture system using a microfluidic culture platform (MCP). Growth cone is stained with 2G13 antibody. Scale bar, 20 mm
(insert scale bar, 10 mm).
(B) Magnified view of the interaction between axons and astrocytes. Astrocytes were stained with GLT1 and axons were stained with bIII-tubulin antibody. Scale
bar, 50 mm.
(C) Axons are sufficient to induce GLT1 upregulation in cultured astrocytes on MCP. Astrocytes were stained with GLT1 and axons were stained with bIII-tubulin
antibody. White arrow: astrocyte with axon contact; yellow arrow; astrocyte without axon contact; Representative two fields were shown from each group. Scale
bar, 50 mm.882 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.
Neuron
Presynaptic Regulation of AstrocytesPrevious in vitro preparations from mixed neuron-glial cultures
had suggested that neuron conditioned medium can directly
activate the expression of GLT1 (Gegelashvili et al., 1997;
Schlag et al., 1998; Swanson et al., 1997) and that soluble
factors may be secreted from neurons to stimulate the expres-
sion of astroglial glutamate transporter. Glutamate has long
been speculated as one of the soluble factors that increase
GLT1 expression, but direct exposure of high concentration of
glutamate in vitro to astrocyte cultures fails to increase GLT1
expression but does alter its cytoplasmic clustering (Nakagawa
et al., 2008; Zhou and Sutherland, 2004). In fact, elevated levels
of glutamate are closely associated with loss of EAAT2 in
chronic neurological injuries including ALS, Huntington’s
disease, and multiple sclerosis, suggesting that other released
factors or altered membrane contact may play more important
roles in mediating axon-induced GLT1 activation. For example,
axon membrane contact can be a potent regulator of develop-
mental astroglial Notch signaling (Eiraku et al., 2005). By using
this isolated neuron astrocyte coculture system, our results
prove that astroglial activation is neuron dependant and that
presynaptic interaction with astroglia including both secretion
and direct membrane contact, transcriptionally activate astro-
glial GLT1.
Recruitment of Kappa-B Motif-Binding Phosphoprotein
(KBBP) to the Promoter Is Required for GLT1
Transcriptional Activation
To evaluate how neurons regulate astroglial GLT1/EAAT2, we
cloned a 2.5 kb upstream promoter of human EAAT2 that shares
high sequence homology (>70%) with GLT1 promoter from
multiple species (Rothstein et al., 2005). To test whether this
2.5 kb promoter behaves similarly as full-length (15 kb) GLT1
genomic promoter in rodent astrocytes, a DsRed EAAT2
promoter reporter (2.5 kb; Figure 3A) was transfected into astro-
cyte cultures derived from BAC GLT1 eGFP transgenic mice
(Regan et al., 2007). After transfection, newly prepared cortical
neurons were plated on transfected astrocytes. As shown in
Figure 3A, the presence of neurons markedly induced the
expression of both DsRed and eGFP reporters in the same astro-
cyte, indicating that the 2.5kb promoter is functional in a rodent
astrocyte environment and contains conserved cis-elements
sufficient for neuron-derived activation signals.
To identify the major promoter regions responsible for neuron-
dependent activation, luciferase promoter reporters were gener-
ated by serial deletion of the 2.5 kb sequence and electroporated
into P2 mouse primary astrocyte cultures. Sequence deletion
from921 to279 (pGL958 versus pGL316 in Figure 3B) sharply
reduced both basal and neuron-dependent promoter activity
(Figures 3B and 3C), with the most significant drop of activityfrom pGL958 to pGL557, indicating that the sequence between
921 to 520 contains primary elements for neuron-dependent
GLT1 promoter activation. Multiple highly conserved transcrip-
tion factor binding sites are present in the region from 921 to
520 by sequence analysis. Site-directed mutagenesis of
pGL958 generated multiple mutant luciferase promoter
reporters, which were examined in astrocyte cultures (Figure 3D).
The 958bp mutant 2 exhibited the greatest reduction in lucif-
erase activity without altering cotransfected b-galactosidase
activity, suggesting that the sequence mutated from 688 to
679 GGGTGGGTGT is essential for GLT1 promoter activity.
Sequence alignment across ten species characterized
GGGTGGGTGT as an evolutionally conserved site among
mammals (Figure S3A). Notably, mutations of putative NF-kB
binding sites within this promoter region had no dramatic influ-
ence on neuron stimulated promoter activation (data not shown).
The requirement of nucleotides 688 to 679 for GLT1
promoter activity was further tested in vivo. GLT1 mRNA tran-
scription is strongly induced during early postnatal development
in rodent brain (Schmitt et al., 1996; Sutherland et al., 1996),
providing an in vivo model to test the GLT1 promoter activation.
A DsRed reporter driven by the wild-type 958bp or 958bp mutant
2 EAAT2 promoters was delivered to brain of young mice using
an adeno-associated virus (AAV) vector to examine in vivo
reporter activation. AAV particles carrying the EAAT2 promoter
DsRed expression cassette were injected into the lateral cere-
bral ventricle of P0 pups of BAC GLT1 eGFP transgenic mice
(Broekman et al., 2006). As shown in Figure 3E, confocal analysis
of coronal brain sections of mice, 3 weeks after injection with
958bp-WT-DsRed containing AAV revealed expression of the
DsRed reporter in astrocytes that also express eGFP reporter.
However, no expression of DsRed was found from brain sections
of mice injected with 958 bp mutant 2-DsRed containing AAV.
Expression of the DsRed was also seen in nearby neurons for
both AAV viruses (data not shown), suggesting that both viruses
are effective in driving the DsRed reporter expression in vivo. The
inability of 958 bp mutant 2 promoter to drive DsRed reporter
expression in astrocytes in vivo confirmed the in vitro results
that the sequence from 688 to 679, GGGTGGGTGT, is
essential for neuron-dependant EAAT2 promoter activity.
The nuclear factors recruited to the GGGTGGGTGT
sequence, were identified by performing a gel shift assay with
nuclear extracts prepared from mouse cortex at developmental
time points prior to GLT1 promoter activation (P2) and after
strong promoter activation (P21). Wild-type and mutant oligos
(45-mer) that only differ in the GGGTGGGTGT were synthesized
and labeled with biotin. As shown in Figure 3F, increased specific
binding with labeled WT oligo was found from P2 to P21 mice
when the GLT1 promoter was strongly activated. The addition(D) Quantitative analysis of axon-induced GLT1 expression (5–10 astrocytes per field, 2–3 field/MCP from total 5–7 MCPs).
(E) Time-lapse recording of astrocytic eGFP (from BAC GLT1 eGFP mice) fluorescence and outgrowth of axons within MCP. Confocal images were collected 24 to
112 hr after coculture. eGFP fluorescence intensity in astrocyte using pseudocolor represention (Image J). Kainate (200 mM) was added to the right side of MCP
after taking images at 68 hr to induce neural injury and axon degeneration. The exchange of solution between chambers is very minimal. Direct treatment of kainite
(200 mM) to astrocyte did not change GLT1 expression and astrocyte viability. Scale bar, 50 mm.
(F) Magnified view of axon and astrocyte interaction in MCP. Examples of axons (yellow arrow) that extend through MCP channels (24–68 hr) and axonal degen-
eration after kainite treatment (68–92 hr). Scale bar, 50 mm.
(G) Quantitative analysis of axon-dependent change of eGFP fluorescence intensity from time-lapse images (5–8 astrocytes per field, 2–3 fields/MCP from total
3–5 MCPs (*p < 0.05, ***p < 0.001, mean ± SEM, one-way ANOVA and Bonferroni post hoc analysis).Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 883
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Figure 2. Glutamate Receptors Are Involved
in Neuron-Dependent GLT1 Expression
(A) Dose-dependent reduction of GLT1 expression
levels induced by TTX (5–50 mM) and iGluR antag-
onist cocktail treatment (7 days) in rat organotypic
spinal cord slice cultures. L: low dose of cocktail
(20 mM MK801 + 30 mM CNQX + 100 mM APV);
H: high dose of cocktail (60 mM MK801 + 90 mM
CNQX + 300 mM APV).
(B) Densitometric analyses of GLT1 immunoreac-
tivity from immunoblot following seven day TTX
or iGluR antagonist cocktail treatment (n = 3).
(C) Effect of individual iGluR antagonists on
neuron-dependent GLT1 expression. Rat spinal
cord cultures were treated with individual iGluR
antagonist for 7 days.
(D) Densitometric analyses of GLT1 immunoreac-
tivity from immunoblot with individual iGluR antag-
onist (n = 3).
(E) Dose-dependent reduction of GLT1 expression
levels induced by mGluR antagonist cocktail treat-
ment (7 days) in rat spinal cord slice cultures. L: low
dose of cocktail (100 mM M196 + 50 mM MPEP); H:
high dose of cocktail (200 mM M196 + 100 mM
MPEP).
(F) Densitometric analyses of GLT1 immunoreac-
tivity from immunoblot with mGluR antagonists
cocktail treatment (n = 3).
(G) Effect of individual mGluR antagonists on neuron-dependent GLT1 expression. Rat spinal cord slice cultures were treated with individual mGluR antagonists
for 7 days.
(H) Densitometric analyses of GLT1 immunoreactivity from immunoblot with individual mGluR antagonists (n = 3). All the immunoblots were quantified in Quantity
One software and plotted in PRISM (***p < 0.001, **p < 0.01, *p < 0.05, error bars represent SEM, one-way ANOVA and Bonferroni test was used).of extraunlabeled WT oligo completely abolished the binding,
suggesting that the binding is specific to this oligo. On the other
hand, no specific binding with labeled mutant (MT) oligo was
found, indicating the change of core sequence from GGGT
GGGTGT to AAATGCCACT abolished the recruitment of specific
nuclear proteins to this cis-element during GLT1 promoter acti-
vation. In addition, no other binding with labeled MT oligo was
observed, suggesting that the replacement of GGGTGGGTGT
with AAATGCCACT does not introduce nonspecific binding
with other nuclear proteins. This direct biochemical evidence
of gel shift result, along with the genetic analysis in Figures 3D
and 3E, demonstrates that the recruitment of nuclear factors to
GGGTGGGTGT is essential for neuron-stimulated GLT1 pro-
moter activity.
To identify the actual transcription factor binding to GLT1 regu-
latory site GGGTGGGTGT, nuclear extracts were affinity purified
with the same oligos used in gel shift analysis. After purification,
proteins bound to the WT or MT oligos were resolved on 4%–
12% PAGE gel and visualized by silver staining. A specific band
with molecular weight between 50 to 75 kDa was only found
with labeled WT oligo but not with MT oligo (Figure 3G), confirm-
ing the results from gel shift analysis. Subsequent trypsin diges-
tion and LC/MS/MS analysis of digested peptides (Figure 3H)
revealed a nuclear protein, kappa-B motif-binding phosphopro-
tein (KBBP, gij1083569), specifically binds to WT oligo.
KBBP was first identified in a T lymphoma cell line that binds to
kappa B enhancer element (GGGGACTTTCC) (Ostrowski et al.,
1994). It is almost 100% homologous with human heteroge-
neous nuclear ribonucleoprotein K (hnRNP K) protein (Ostrowski884 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.et al., 1994). HnRNP K protein plays diverse roles in transcription,
RNA splicing, and signal transduction through its interaction
with many protein partners, including protein kinases, transcrip-
tional factors, and DNA/RNA (Bomsztyk et al., 2004). Notably,
although the original kappa B enhancer element GGGGACT
TTCC share partial homology with the KBBP binding sequence
GGGTGGGTGT on GLT1 promoter, it is sufficient to compete
out GGGTGGGTGT induced specific binding with KBBP in a
dose-dependent manner (Figure S3B). In addition, further muta-
tion of GGG to AAA on KBBP binding sequence GGGTGGGTGT
also abolished GLT1 promoter activity (Figure S3C), suggesting
that these nucleotides are critical for KBBP binding and GLT1
promoter activity. As the mouse homolog of human hnRNP K,
KBBP protein may also participate in transcription or RNA
splicing. Expression of KBBP in astrocytes in vivo was first
examined by using an antibody against human hnRNP K.
Cortical immunoreactivity for KBBP in both P2 and P21 BAC
GLT1 eGFP mice shows neuronal and astroglial immunolocaliza-
tion. Notably, KBBP expression was barely detectable in P2
astrocytes and dramatically increased in astroglia from P2 to
P21, which is identical to the very large increase in astroglial
GLT1 promoter activity (indicated by eGFP reporter intensity) in
the same astroglia (Figure 4A). The significant correlation
between increased expression of astroglial KBBP and GLT1
promoter/protein (Figure 4B) during early postnatal development
suggests that KBBP may play an important role in transcriptional
regulation of GLT1. Interestingly, KBBP expression in cultured
astrocytes was also induced by neurons, coupled to the increase
of GLT1 (Figure 4C); the coupled increases of KBBP and GLT1
Neuron
Presynaptic Regulation of AstrocytesA
B C
D E
F
G H
Figure 3. Recruitment of Kappa B-Motif Binding Phosphoprotein (KBBP) to GLT1 Promoter Is Required for Its Activation
(A) A 2.5 kb of human EAAT2 promoter is sufficient for neuronal stimulation in mouse astrocyte environment. The EAAT2 2.5 kb promoter-DsRed reporter and
GLT1 genomic promoter-eGFP reporter were both activated in astrocytes following coculture with neurons identified by bIII-tubulin immunostaining.
(B) Identification of the regions essential for the basal activity of human EAAT2 promoter by serial deletion of human EAAT2 promoter (n = 5–7). ***p < 0.001;
mean ± SEM.
(C) Promoter sequence from 958 bp to 557 bp is mainly responsible for neuron-dependent GLT1 promoter activation in primary astrocytes (n = 4–8)., =
astrocytes alone;- = astrocytes and neurons. ***p < 0.001; mean ± SEM.
(D) Mutagenesis of GGGTGGGTGT from 688 bp to 679 bp almost completely abolished basal and neuron-dependent GLT1 promoter activity in vitro (n = 6–8).
For luciferase assay, luciferase promoter reporters were first electroporated into cultured astrocytes and then freshly prepared neurons were plated on the top of
transfected astrocytes. b-galactosidase was cotransfected for normalization. ***p < 0.001, **p < 0.01, one-way ANOVA and Bonferroni test was used.
(E) Mutagenesis of GGGTGGGTGT from 688 bp to 679 bp abolished GLT1 promoter activation (indicated by DsRed reporter expression) in astrocyte in vivo
during early postnatal development. Astrocytes were identified by positive eGFP expression (20–30 astrocytes examined per serial section/mouse for total four
mice each).
(F) Mutagenesis of cis-element GGGTGGGTGT abolished its specific binding to nuclear factors during GLT1 promoter activation in early postnatal development.
(G) Affinity purification by using wild-type oligo GGGTGGGTGT but not the mutant oligo found unique nuclear protein from P21 mice cortex nuclear extracts.
(H) Trypsin digestion and LC/MS/MS identified Kappa B-motif binding phosphoprotein (KBBP) that specifically binds to GGGTGGGTGT. The red-colored amino
acid sequences are small peptide sequences identified from LC/MS/MS that also match with KBBP sequence in NCBI.Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 885
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in vivo.
Small interference RNA (siRNA) specifically against KBBP was
developed that effectively reduced KBBP expression level to
10% of that in control (Figure 4D; Moumen et al., 2005), which
results in significantly reduced GLT1 expression in astrocytes
on neuron-astrocyte coculture MCP (Figure 4E). We further
tested whether a decrease of KBBP expression in astrocytes
also reduces GLT1 promoter activity in vivo. To selectively
silence astroglial KBBP, AAV particles that carried an expression
cassette with the KBBP gene in the antisense orientation driven
by the GFAP promoter, along with AAV particles that carried
A B C
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Figure 4. KBBP Is Essential and Sufficient for Neuron-Dependent Transactivation of GLT1
(A) Expression of KBBP protein in astroglia in vivo. KBBP protein expression was minimal in P2 astroglia (BAC GLT1 eGFP reporter, white arrows) and was mark-
edly induced in cortical astrocytes during early postnatal development, along with astroglial BAC-GLT1 eGFP expression (white arrows). Scale bar, 10 mm.
(B) Quantitative correlation of KBBP expression levels and GLT1 promoter activity in astroglia during early postnatal development. Positive linear relationship of
KBBP expression levels and eGFP intensity was found. The KBBP immunoreactivity and eGFP fluorescence intensity was quantified in Image J (20 astrocytes
examined per serial section/mouse for total 4 mice).
(C) KBBP expression in astrocytes is induced by the presence of neuron. Neurons and astrocytes were cocultured for 1 week before sample collected. Positive
control: mice brain lysate.
(D) Development of shRNA that specifically silences KBBP expression. shRNA against KBBP results in over 90% less of KBBP expression in 3T3 NIH cells.
(E) Silencing of KBBP expression by shRNA reduced GLT1 expression in astrocyte on neuron-astrocyte coculture MCP. shRNA-expressing astrocytes were iden-
tified by coexpressed eGFP from shRNA construct. GLT1 expression and neuronal processes were visualized by GLT1 or bIII-tubulin immunostaining, respec-
tively. Scale bar, 20 mm.
(F) AAV mediated expression of KBBP antisense in vivo reduced GLT1 promoter activity during early postnatal development. AAV8-GFAP-KBBP-A/S and AAV8-
GFAP-DsRed particles were coinjected into cerebral lateral ventricle of P0 pups of BAC GLT1 eGFP transgenic mice. AAV8-GFAP-luciferase-A/S serves as anti-
sense control for AAV8-GFAP-KBBP-A/S. Antisense expressing astrocytes were identified by DsRed reporter expression (20–30 astrocytes examined per serial
section/mouse for total 4 mice each). Scale bar, 50 mm (one-way ANOVA with Bonferroni post hoc analysis, **p < 0.01, ***p < 0.001; mean ± SEM).
(G) Overexpression of KBBP in astrocytes increases GLT1 expression with the presence of neurons. L: luciferase overexpression; K: KBBP overexpression.
Neurons were plated on transfected astrocyte cultures 2 days posttransfection and kept for 1 week.886 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.
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promoter, were intraventricularly injected into new born (P0)
BAC GLT1 eGFP transgenic mice. AAV particles carrying lucif-
erase in the antisense orientation served as a control. KBBP anti-
sense was highly effective at silencing KBBP expression in
cultured astrocytes (Figure S4C). As shown in Figure 4F, KBBP
antisense, but not luciferase antisense, effectively silenced
KBBP expression in vivo. GLT1 promoter activity in KBBP anti-
sense-expressing astrocytes, identified by DsRed, was signifi-
cantly reduced as indicated by reduced eGFP intensity
(Figure 4F, I and II, shown by yellow arrow) compared to that in
untransduced astrocytes (shown by white arrow) while GLT1
promoter activity in luciferase expressing astrocytes was unal-
tered (Figure 4F, III and IV, shown in yellow arrow). In aggregate,
the loss-of-function analysis of KBBP by RNAi and antisense in
astrocytes, along with the promoter mutagenesis analysis, indi-
cate that recruitment of KBBP to the GLT1 promoter is required
for GLT1 transcriptional activation in vivo.
We next determined if overexpression of KBBP could
concomitantly alter GLT1 expression in astrocyte cultures.
KBBP and luciferase overexpression constructs were prepared
and electroporated into cultured astrocytes. As shown in
Figure 4G, overexpression of KBBP, but not luciferase, was suffi-
cient to increase GLT1 expression in the presence of neurons,
though overexpression of KBBP itself was not sufficient to
induce the GLT1 expression. In addition, direct treatment of
cultured astrocytes with DHPG (50 mM), the selective agonist
for mGluR 1/5, increases both GLT1 and KBBP mRNA levels
(Figures S4A and S4B), indicating that mGluR 1/5 may play
more dominant role in neuron-dependent GLT1 upregulation.
Although direct treatment of physiological GluR agonist gluta-
mate failed to increase the GLT1 expression, this could be due
to the quick uptake of extracellular glutamate by GLAST in
cultured astrocytes. These results are consistent with our obser-
vations that astroglial KBBP and GLT1 are expressed in parallel
in vivo during early postnatal and synaptic maturation. This hints
that the maturation of synapse might influence astroglial gene
activation and expression of GLT1. Conversely, an alteration of
this pathway due to the loss of presynaptic influence of neurons
on astrocytes could be an important event linking neural injury to
astroglial synaptic function.
In Vivo Neuron/Axon Denervation Leads to GLT1
Transcriptional Dysregulation through Reduction
of KBBP Expression
In order to evaluate the in vivo effect of altered synaptic coupling of
neurons to astroglia, we investigated the alterations of astroglial
GLT1 gene activation and regulation by KBBP in response to
synaptic disruption by using several in vivo models including acute
axon denervation induced by corticospinal tract lesion, ricin-
induced acute motor neuron degeneration and the chronic neuro-
degeneration ALS mouse model employing SOD1 G93A mice.
Corticospinal Tract Transection
Corticospinal tracts originating from glutamatergic upper motor
neurons possess excitatory presynaptic terminals on spinal
cord interneurons and lower motor neurons that are modulated
by perisynaptic astroglial GluTs. This pathway allows directin vivo assessment of astroglial transporter expression in
response to the loss of axonal signals induced by spinal cord
transection. Thoracic cord (segment 9) transection was per-
formed three weeks after mice received bilateral injection of Flu-
ororuby (FR) into motor cortex to label corticospinal tracts by
anterograde FR transport. One week after transection, thin hori-
zontal sections of spinal cord were prepared and FR signals were
examined to assess axon degeneration. Above the surgical
lesion, abundant FR labeled axons, typical for corticospinal tract
innervation, were found bilaterally in spinal cord white matter,
projecting to gray matter neurons at each segment (Figure 5A, I).
FR-labeled neurons were also observed in gray matter
(Figure 5A, II). In contrast, FR signals (including labeled axons
and gray matter neurons) were reduced in the cord well below
the lesion site in lumbar spinal cord (Figure 5A, III). Quantitative
analysis revealed that more than 70% of FR labeled corticospinal
axons in lumbar cord were depleted as early as 7 days following
spinal transection (Figure 5A). GLT1 protein expression in lumbar
cord of lesioned mice was markedly reduced compared to that of
control mice (Figure 5B). A pronounced loss of GLT1 immunos-
taining was also observed in coronal sections of lesioned lumbar
cords from BAC GLT1 eGFP mice. GLT1 promoter activity, as
reflected by eGFP fluorescence intensity in coronal sections of
lumbar cord of lesioned BAC GLT1 eGFP mice, was focally
reduced (Figures 5C and 5D) in single astrocytes. These sharp as-
troglial changes were localized to regions with diminished
synaptic terminals, as identified by the loss of presynaptic
terminal marker vesicle glutamate transporter 1 (VGluT1), VGluT2
(Figure S5A) and preservation of postsynaptic marker PSD95.
Overall, the loss of KBBP in individual astroglia (Figure 5E,
yellow arrow) correlated with a decrease in GLT1 promoter-
reporter eGFP intensity in same cells in lesioned lumbar cord
(Figure 5E), along with loss of GLT1 protein (Figure 5B). The as-
troglial changes all followed the loss of presynaptic terminals.
These in vivo studies demonstrate that presynaptic terminals
act to maintain astroglial KBBP expression, which in turn acti-
vates GLT1 expression. Furthermore, these data provide a
pathway by which abnormal axon/presynaptic signaling can alter
astroglial synaptic integrity.
Neurotoxin Lesion
Neurodegeneration could alter the physiologic axon/astrocyte
communication required for astroglial synaptic maintenance.
The neurotoxin ricin, an extremely potent protein synthesis inhib-
itor, has been well established as a model for selectively lesion-
ing discrete populations of motor neurons, through retrograde
transport. In order to examine the response of individual astroglia
in vivo, to the focal loss of spinal motor neurons, and their recur-
rent axon collaterals, we injected selected peripheral nerves with
the toxin. Femoral nerves (originated from lumbar cord 2–4) of
BAC GLT1 eGFP mice were dipped into fluororuby (FR) solution
or mixture of ricin and FR solution unilaterally so that the change
of GLT1 promoter activity in response to motor neuron death
could be directly assessed at the same segment. As shown in
Figure 6A, motor neurons were clearly labeled with FR in the
control side of L2–L4 cord sections but not in the ricin injected
side due to degeneration of motor neurons 1 week following
injection (magnified view in Figure 6C). Mice received unilateralNeuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 887
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(Movie S1), suggesting that retrograde ricin indeed induced
dramatic motor neuron degeneration. The focal, selective loss
of motor neurons and their recurrent collaterals was apparent
on surrounding astroglia-eGFP fluorescence intensity was 30%
reduced in ricin lesion side compared to that of control side
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Figure 5. Corticospinal Tract Presynaptic Degeneration Induced by Spinal Cord Transection Results in Loss of GLT1 Protein and Promoter
Activity
(A) Thoracic transection induces massive degeneration of descending axons. Descending corticospinal tracts were shown by anterograde transport of FR from
motor cortex. Abundant FR labeled axons/neurons (black arrow) were observed in white/gray matter of spinal cord above the lesion site (I, scale bar, 0.5 mm).
Quantitative analysis of FR-labeled axon length showed that 70% of axons degenerated in lesioned mice compared to sham control mice (n = 5). Representative
images with FR labeled axons/neurons are shown in II and III, scale bar, 20 mm.
(B) Thoracic spinal cord transection leads to loss of GLT1 protein in lumbar spinal cord by both immunoblotting (n = 3) and immunostaining. Scale bar, 20 mm.
(C) Single astrocyte analysis in vivo revealed loss of GLT1 promoter activity in astrocytes surrounding degenerated axons/presynaptic terminals of lesioned BAC
GLT1 eGFP mice. Presynaptic complexes were identified by double staining for presynaptic VGluT1 and postsynaptic PSD95. Scale bar, 20 mm.
(D) Quantitative analysis of the eGFP fluorescence intensity in lumbar cord astrocytes of lesioned mice (nR 93).
(E) Axon degeneration decreases KBBP immunostaining intensity in lumbar cord astrocytes of lesioned BAC GLT1 eGFP mice. Scale bar, 20 mm.
(F) Quantitative analysis of the KBBP immunostaining intensity in lumbar cord astrocytes of lesioned mice (nR 45) (***p < 0.001, mean ± SEM).888 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.
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not due to astroglial death, as abundant GFAP immunoreactivity
was still found in the astroglia with reduced eGFP on the lesioned
side of the spinal cord (Figure 6C). Quantitative single astrocyte
analysis of confocal images of thin section of L2-L4 cord from
BAC GLT1 eGFP mice administrated with unilateral ricin also
found 50% reduced KBBP immunoreactivity in astroglia with
reduced eGFP intensity (Figures 6E and 6F). Ricin-induced
motor neuron degeneration abolished its signaling to
surrounding astroglia, likely mediated by both motor neuron
dendrites and axon collaterals, which suggests that neuronal
inputs are necessary to maintain KBBP expression levels and
subsequent transactivation of the GLT1 promoter.
G93A SOD1 ALS Mouse Neurodegeneration
Severe loss of GLT1 protein has been observed in SOD1 G93A
transgenic rodents (Howland et al., 2002), a model of familial
ALS, and in the R6/2 mice model of Huntington’s disease
(Lievens et al., 2001). The mechanism for this loss in these animal
models remains unexplained. Total spinal cord EAAT2 mRNA
levels were not found abnormal in prior ALS studies (Bristol
and Rothstein, 1996). However, these past studies were techni-
cally limited due to post mortem tissue artifacts and the use of
low-resolution, bulk tissue homogenization and non-in situ
approaches—all which limit the ability to detect focal astroglial
abnormalities known to occur in human and rodent ALS (How-
land et al., 2002; Rothstein et al., 1994a). Similar to the acute cor-
ticospinal lesion experiments and ricin toxin lesion, the loss of
GLT1 protein in rodent models of ALS is focal to the region of de-
generating motor neurons and spreads along the lumbar spinal
cord. To better detect focal GLT1 mRNA alterations in astroglia,
in situ hybridization of GLT1a and GLT1b, the two major GLT1
transcripts was performed in lumbar spinal cord of SOD1
G93A transgenic rat (Figure 7A). GLT1a mRNA is far more
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Figure 6. Motor Neuron Degeneration Induced by Neurotoxin Ricin Leads to Reduced GLT1 Promoter Activity and KBBP Expression
(A) Visualization of motor neurons in ventral horn of lumbar spinal cord by fluoro-ruby (FR). Femoral nerves were exposed and dipped into FR solution (10%) to
allow retrograde transport of FR into motor neurons. Scale bar, 50 mm (insert scale bar, 100 mm).
(B) Unilateral administration of ricin induced reduction of eGFP intensity.
(C) Thin coronal sections of L2–L4 cord of BAC GLT1 eGFP mice was prepared and immunostained with GFAP antibody one week following unilateral admin-
istration of ricin. Reduced eGFP intensity but not the GFAP immunoreactivity was found in ricin side. Scale bar, 100 mm (50 mm for magnified image).
(D) Fluorescence intensity of eGFP in individual astroglial from ricin and control sides were measured in Image J and plotted using Prism (20–25 astrocytes per
serial section/mouse for total 10 mice) (*p < 0.05, mean ± SEM, Student’s t test).
(E) Single astrocyte analysis in vivo revealed reduction of KBBP immunoreactivity in astroglia with reduced eGFP intensity. Thin coronal sections of L2–L4 cord of
BAC GLT1 eGFP mice was prepared and immunostained with KBBP antibody one week following unilateral administration of ricin. Motor neurons were identified
by FR in control side.
(F) KBBP immunoreactivity in astroglia with reduced eGFP intensity was measured in Image J and plotted in Prism (20–25 astrocytes per serial section/mouse for
total 10 mice). Scale bar, 20 mm. Yellow arrow: astroglia in control side; White arrow: astroglia in ricin side. (Student’s t test: ***p < 0.001, mean ± SEM).Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 889
Neuron
Presynaptic Regulation of AstrocytesA
E
B
C
D
F
G H
Figure 7. GLT1 Transcriptional Dysfunction Contributes to the Loss of GLT1 Protein in SOD1 G93A Rodents
(A) In situ hybridization of major GLT1 transcripts in lumbar cord of end-stage (125 days) SOD1 G93A rat. Scale bar, 0.5 mm.
(B) Quantitative analysis of in situ signals of GLT1a and GLT1b (20–30 areas examined per serial section per rat, n = 3 rats).
(C) QRT-PCR analysis of GLT1 mRNA levels in lumbar cord of SOD1 G93A mice.
(D) QRT-PCR analysis of GFAP mRNA levels in lumbar cord of SOD1 G93A mice. Total RNA from lumbar spinal cord of SOD1 G93A mice at different stages
(60 days, 90 days, 120 days) was prepared. The GLT1 and GFAP mRNA levels were determined by QRT-PCR with GLT1- or GFAP-specific probe. The amount
of RNA used in QRT-PCR was normalized by b-actin mRNA and 18 s RNA. The GLT1 or GFAP mRNA levels of WT mice at 60 days was used as calibrator for
mRNA comparison (n = 7–12) (two-way ANOVA with post hoc Bonferroni: *p < 0.05, **p < 0.01, ***p < 0.001, mean ± SEM).
(E) Loss of GLT1 promoter activity indicated by eGFP intensity in astrocytes of ventral lumbar cord of BAC GLT1 eGFP X SOD1 G93A mice. No apparent loss of
astroglia was observed by GFAP immunostaining.890 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.
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(Berger et al., 2005). There was a pronounced focal loss of both
GLT1a (70% loss compared to WT; Figure 7B) and GLT1b (50%
loss compared to WT; Figure 7B) mRNA transcripts in the ventral
horn of the SOD1 G93A rat spinal cord, similar to reports of GLT1
protein (Howland et al., 2002). In addition, quantitative real time
PCR analysis of GLT1 mRNA from lumbar spinal cord of SOD1
G93A mice at different stage of disease progression (60, 90,
120 days) also showed that GLT1 mRNA was reduced to 65%
of control at disease onset and further decreased to 40% of
control as disease progressed to end stage (Figure 7C). In
contrast, GFAP mRNA levels increased gradually as disease
progressed to end stage (Figure 7D). To better evaluate alter-
ations of GLT1 regulation at the single-cell level, the SOD1
G93A mice were mated to the GLT1 BAC eGFP reporter mice.
The presence of the BAC-eGFP promoter reporter did not
change the course of disease, with mice developing disease
at approximately 90 days of age and reaching end stage at
125 days of age (n = 20). BAC GLT1 eGFP 3 SOD1 G93A
mice were sacrificed at various time points and eGFP expres-
sion, as a reflection of GLT1 promoter activity (Regan et al.,
2007), was examined and quantified by confocal microscopy
of serial thin sections from lumbar cord (Figure 7E). A profound
decrease of astroglial GLT1 promoter activity, indicated by
a more than 60% loss of eGFP fluorescence intensity, was found
in ventral gray matter of BAC GLT1 eGFPxSOD1 G93A mice,
especially in ventral gray matter-localized astroglia near motor
neurons from end-stage (127 days) animals (Figure 7F). The
loss of GLT1 promoter activity/eGFP fluorescence was the result
of transcriptional dysfunction in these spinal cord astroglia,
rather than cell death as increased GFAP immunostaining signal
was observed from astrocytes with decreased eGFP fluores-
cence (Figure 7E), as well as increased GFAP mRNA levels in
lumbar spinal cord from end-stage SOD1 G93A mice (Figure 7D).
Notably, there is a profound loss of presynaptic terminals in
this transgenic model as a result of the loss of presynaptic corti-
cospinal tract terminals, spinal interneurons and recurrent
collaterals from motor neurons, as reflected by a decrease in
synaptophysin expression (Figure S4A; Morrison et al., 1998).
To determine if there was a relationship between neural injury/
synaptic loss and the alteration in regulation of astroglial
synaptic control in this disease model, the expression level of as-
troglial KBBP in ventral lumbar cord of BAC GLT1 eGFP3 SOD1
G93A mice (n = 5) was also examined. As shown in Figure 7G,
KBBP immunostaining and GLT1 promoter activity/eGFP
reporter fluorescence was diminished in astrocytes from ventral
lumbar cord of SOD1 G93A mice. The intensity of eGFP fluores-
cence and KBBP immunostaining in individual astrocytes (nR 25)
were highly correlated (Figure 7H). Decreased KBBP expres-
sion levels (<20000, arbitrary units) were correlated with lower
levels of eGFP fluorescence intensity (<25,000, arbitrary units),which was also found in the corticospinal transection and ricin
models described above. GLT1 transcriptional activation,
KBBP immunoreactivity and eGFP expression levels were unal-
tered in dorsal horn astrocytes from the BAC GLT1 eGFPxSOD1
G93A mice (data not shown).
In summary, KBBP is a neuron-dependant downstream
nuclear factor that regulates astroglial GLT1 transcription as
determined by (1) in vitro and in vivo genetic analysis of KBBP
modulating GLT1 expression, (2) pharmacologic and synaptic
activity regulated expression of GLT1 transcription, (3) correla-
tion of developmental KBBP and GLT1 expression levels in as-
troglia, and (4) correlation of altered in vivo presynaptic inputs
to astroglial KBBP and GLT1 promoter activation by employing
models of synaptic denervation including corticospinal lesion,
single neuron toxin lesion and an animal model of ALS. These
studies provide a molecular mechanism for abnormal astroglia
in neurodegeneration: alteration/loss of synaptic terminals
decreases the astroglial expression of KBBP, which ultimately
negatively regulates astroglial expression of the perisynaptic
GLT1.
DISCUSSION
In this study, we systematically dissected the mechanisms
underlying neuronal regulation of astroglia, by examining the
neurotransmitter transporter EAAT2/GLT1 in complementary
in vitro and in vivo models. Our results show that axonal
interactions with astroglia are sufficient and necessary for
neuron-dependent astroglial GLT1 transcriptional activation.
Physiologically, presynaptic-based activation of astroglial
GLT1 transcription could serve as a neuron-glial coupled mech-
anism ultimately for the modulation of postsynaptic activation at
excitatory synapses, by regulating the synthesis of GLT1 and its
subsequent expression on astroglial membranes. The current
study identified a critical downstream astroglial nuclear factor
KBBP and demonstrated that the recruitment of KBBP to the
GLT1 promoter is required for neuron-dependent GLT1 tran-
scriptional activation. Although prior studies, of cultured fetal
astrocytes and small promoter fragments, suggested that
NF-kB could modulate this promoter (Sitcheran et al., 2005;
Su et al., 2003), physiologically relevant neuron-stimulated
promoter activation was not dependent upon that transcription
factor in the current study. Normal developmental maturation
of new synapses correlated with the activation of astroglial
GLT1, via new KBBP expression. The loss of presynaptic
signaling to astrocytes, as a result of acute axon transection or
neuronal death in an acute or chronic neurodegeneration model,
abolished signal transmission from neurons to astroglia leading
to transcriptional dysregulation: decreased astroglial KBBP,
subsequent diminished GLT1 promoter activation and loss of
GLT1 protein expression.(F) Quantitative analysis of eGFP fluorescence intensity in astrocytes of BAC GLT1 eGFP X SOD1 G93A at different ages (35 astrocytes per serial section/mouse
for total 20 mice).
(G) Decreased expression levels of KBBP in astrocytes with reduced eGFP fluorescence intensity in ventral lumbar cord of BAC GLT1 eGFP X SOD1 G93A mice.
Scale bar, 20 mm (insert scale bar, 50 mm).
(H) Linear regression curve between KBBP immunoreactivity and eGFP intensity in astroglia. KBBP immunoreactivity and eGFP fluorescence intensity was
measured in Image J and plotted in SigmaPlot. (nR 25) (Student’s t test: ***p < 0.001, mean ± SEM).Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc. 891
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presynaptic secretion and membrane contact. Previous in vitro
preparations of simple mixed neuron-glial cultures had sug-
gested that neuron secreted factors could activate astroglial
differentiation and expression of GLT1 (or GLAST) (Gegelashvili
et al., 1997; Munir et al., 2000; Schlag et al., 1998). The elements
responsible for this neuron-glial interaction, e.g., dendrites,
axons, synapses, receptor subtypes, are not known. In the
current study, using the microfluidic culture platform, we were
able to identify axon/presynaptic inputs as a distinct regulator
of astroglial transporter activation, via KBBP. In parallel, we
also identified comparable presynaptic inputs as a necessary
component of KBBP activation of astroglial GLT1 in vivo.
The mechanism of GLT1 regulation appears to involve both gluta-
mate receptors as well as unspecified membrane-membrane
interactions. For example, axon-glial membrane contact can be
a potent regulator of developmental astroglial Notch signaling
(Eiraku et al., 2005). In addition, neurons may also modulate the
nontranscriptional processes in astrocyte-specific synaptic
functions such as trafficking and membrane stabilization or clus-
tering of GLT1 protein as suggested by in vitro studies (Nakagawa
et al., 2008; Zhou and Sutherland, 2004).
Downstream signaling pathways between GluRs and KBBP
recruitment to the GLT1 promoter are not yet understood. As
KBBP can be phosphorylated by multiple upstream protein
kinases (Bomsztyk et al., 2004), signals may be transmitted
from GluRs to KBBP by protein kinase mediated phosphoryla-
tion. KBBP likely acts as a docking platform to aid in actions of
other transcription factors with the GLT1 promoter. The interac-
tion of KBBP with other astroglia-specific transcription factors
remains to be characterized.
Expression of neurodegenerative disease proteins, including
mutant SOD1, Huntington’s disease protein, and spinocerebellar
ataxia 7 protein—have all implicated astroglial dysfunction in
disease propagation (Lobsiger and Cleveland, 2007) with
unclear mechanisms why astroglia becomes dysfunctional in
diseases. Although multiple mechanisms likely contribute to
motor- and interneuron death in ALS and its familial transgenic
models, astroglial loss of GLT1/EAAT2 in both sporadic and
familial ALS represents a common mechanism for disease prop-
agation. Notably, a high percentage (R50%) of motor/inter
neuron degeneration has occurred at the time when symptoms
start to develop (Martin et al., 2007), which is consistent with
the loss of synaptophysin we observed. Synaptic stripping and
loss of presynaptic inputs to neurons are described in animal
models of neurodegeneration/neural injury (Blinzinger and
Kreutzberg, 1968; Trapp et al., 2007) and in humans (Graeber
et al., 1993). Our current studies suggest that disruption of the
neuron-astroglial unit, specifically the loss of synaptic termi-
nals/synaptic activity, alters normal astroglial function. It is likely
that changes in synaptic terminals induce astroglial dysfunc-
tion—such as altered GLT1 expression and other synaptically
relevant proteins which leads to additional neuronal injury and
thereby acts as a feed forward mechanism to propagate
neuronal disease/injury. A more complete understanding of the
global transcriptional changes in astrocytes following neuronal
injury may help identify other pathways by which astroglia
contribute to normal and abnormal brain function.892 Neuron 61, 880–894, March 26, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Cultures and Transfection
Cortical astrocyte cultures were prepared from P2–4 mouse pups. Cortical
neuronal cultures were prepared from E14–16 mouse embryos. For astro-
cyte-neuron coculture on the MCP, chambers were first assembled on coated
glass-bottom dishes before culturing as previously described (Park et al.,
2006). Neuronal cultures (>1 3 106 cells) were directly seeded on the right
side of the MCP (N in Figure 1A) and GDNF (10 ng/ml) was applied to the left
side for 3–5 days to induce axon outgrowth. GDNF was removed and astro-
cytes (precultured for 7-10d) were then plated on the left side of the MCP
(before axons grow through the channels) for another 3–5 days. Electropora-
tion of astrocyte cultures with promoter reporter and shRNA constructs was
performed by using an Amaxa device (Gaithersburg, MD). In each reaction,
2–43 106 cells and 4 mg DNA was used. Organotypic spinal cord slice cultures
were prepared and treated as described previously (Rothstein et al., 1993).
Immunostaining and Microscopy
Cultures were directly fixed in the MCP with 4% paraformaldehyde (30 min).
After three rinses in PBS, cells were treated with blocking buffer (0.4% BSA,
5% goat-serum, and 0.2% Triton X-100 in PBS) for 20 min at room tempera-
ture. Primary antibodies GLT1 (rabbit, 1:1000), bIII-tubulin (mouse, 1:1000),
Synaptin I (rabbit, 1:1000), 2G13 (mouse, 1:50) were incubated overnight at
4C in blocking buffer. Anti-mouse Alexa 488-conjugated antibody or anti-
rabbit Alexa 555-conjugated antibody (1:1000) were added for 90 min at
room temperature. For immunohistochemistry, animals were perfused with
4% paraformaldehyde. Tissues were dissected and kept in 4% paraformalde-
hyde overnight. After PBS wash, tissues were cryoprotected in 30% sucrose
overnight and embedded in tissue freezing medium. Except for spinal cord
from transection lesioned mice (15 mm horizontal section), serial coronal
sections (30 mm for brain and 15 mm for spinal cord) were prepared. Sections
were incubated in blocking buffer (Tris-Cl [pH 7.4], 5% goat serum, 0.1% Triton
X-100, 1% BSA) for 60 min. Primary antibodies KBBP (1:1000), GLT1 (1:500),
GFAP (1:200), VGluT1 (1:200), PSD95 (1:200) were incubated overnight at 4C
in blocking buffer. Anti-mouse/rabbit Alexa 555-conjugated antibody or anti-
mouse/rabbit Alexa 633-conjugated antibody (1:1000) were added for
90 min at room temperature. All double staining was performed sequentially.
Confocal images of stained MCP or tissue sections were taken on Zeiss
LSM510 Meta. For live-cell time-lapse imaging on the MCP, astrocytes from
BAC GLT1 eGFP mice were used. Images were taken from 24 to 112 hr post-
seeding of astrocytes. Images were taken simultaneously on both green and
transmitted filter. eGFP fluorescence intensity was digitally converted into
a rainbow pseudocolor (Image J).
Plasmids and Virus Preparation
Fragments of GLT1/EAAT2 promoter sequence was amplified with pfu and
cloned into XhoI/HindIII site of pGL4.14 vector to generate luciferase promoter
reporters. Individual sites on the GLT1/EAAT2 promoter were mutagenized by
gene tailor system (Invitrogen, Carlsbad, CA) and cloned into pGL4.14. GLT1/
EAAT2 promoter DsRed reporter was generated by inserting GLT1/EAAT2
promoter fragment into XhoI/HindIII site of pDsRed-Express-1. GLT1/EAAT2
promoter fragment and DsRed cassette were prepared by XhoI/XbaI digestion
and then cloned into modified pAM/CAG-pL-WPREBGH-polyA viral vector for
final AAV construct. KBBP and NS (nonspecific) small hairpin RNA (shRNA)
was synthesized and cloned into pGSU6-GFP to test its efficiency. KBBP
and luciferase antisense was reversely amplified from pGK5 and pGL4.14 by
pfu and cloned into XhoI/EcoRI site of pAM-pGFA-pL-WPREBGH-polyA. For
overexpression constructs of KBBP and luciferase, KBBP and luciferase
cDNA was subcloned into the EcoRI/XhoI site of pcDNA 3.1/myc-His vector.
Recombinant AAV8 was packaged in cultures of HEK293T cells. Adeno helper
plasmid (pFD6), AAV helper encoding serotype 8 (pAR8), and the AAV trans-
gene vector plasmid were transfected into HEK293T cells using polyfect
(QIAGEN, Valencia, CA). At 72 hr after transfection, cells were pelleted by
centrifugation and resuspended in 10 mM Tris-cl (pH 8.0). AAV8 viral particles
were purified by density gradient centrifugation (60,000 rpm, 2 hr) in iodixinol
after lysing cells, followed by centrifugation in Millipore Ultrafree 15 filter
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tive RT-PCR using primers and a probe specific for the WPRE sequence.
Quantitative RT-PCR
Total RNA from either cultured cells or tissues were prepared by using Abso-
lutely RNA Miniprep Kit from Stratagene. Total RNA were converted to cDNA
and TaqMan premade gene-specific probes for were used for PCR process.
18 s rRNA was used as endogenous marker to normalize the RNA quantity.
Gel Shift and Affinity Purification
Wild-type and mutant oligos (45-mer) from 707 to 663 of EAAT2 promoter
were directly synthesized with biotin added to the 50 end. Mutant oligos have
sequence from 688 to 679 GGGTGGGTGT replaced with AAATGCCACT.
Nuclear extracts were prepared by using NE-PER Nuclear and Cytoplasmic
Extraction Reagent (Pierce Biotechnology, Rockford, IL) from freshly dissected
cortex of P2 and P21 wild-type mice. Gel shift was performed with procedures
described in Lightshift Chemiluminescent EMSA kit (Pierce Biotechnology,
Rockford, IL). In each reaction, 2 ml (50 fmol/ml) biotin labeled oligos with
100-fold unlabeled oligo, and 5mg nuclear extract were added. The same oligos
and nuclear extracts from P21 mice cortex were used for affinity purification.
Affinity purification was performed using a mMACS FactorFinder kit (Milteny
Biotec, Auburn, CA). For each reaction, 50 mg of nuclear extracts and 10 ml
(5 pmol/ml) biotin labeled oligos were mixed and two reactions were pooled
together for WT or mutant oligos, respectively. Elutions were resolved on
4%–12% gradient gel and stained by using SilverSNAP Stain for Mass Spec-
trometry (Pierce Biotechnology, Rockford, IL). Silver stained bands were
excised and digested by trypsin, and subjected to LC/MS/MS analysis at Johns
Hopkins University Mass Spectrometry Facility (Baltimore, MD).
In Situ Hybridization
Lumbar spinal cords (L4–5) were carefully dissected from end-stage
(135 days) SOD1 G93A and age-matched control rats and snap-frozen into
80C. Coronal sections (10 mm) of lumbar cord were prepared. Specific
30UTR cRNA probes (400 bp) for GLT1a and GLT1b were amplified from
mouse genomic DNA and in vitro transcribed, respectively. The exact location
of GLT1a and GLT1b were previously described (Berger et al., 2005; Rothstein
et al., 1994b). Single-label nonisotopic in situ hybridization was performed with
digoxigenin (DIG)-labeled cRNA probes and alkaline phosphatase (AP) detec-
tion as described previously (Rothstein et al., 1996).
Animals, Virus Injection, and Surgery
Wild-type Sprague-Dawley rats and C57/B6 mice, SOD1 G93A transgenic rats
and mice, BAC GLT1 eGFP transgenic mice were used for in vivo experiments.
The care and treatment of animals in all procedures strictly followed the NIH
Guide for the Care and Use of Laboratory Animals and the Guidelines for the
Use of Animals in Neuroscience Research and the Johns Hopkins University
IACUC. Rats and mice were housed at standard temperature (21C) and in
a light controlled environment with ad libitum access to the food and water.
BAC GLT1 eGFP reporter mice were crossed with SOD1 G93A mice to obtain
double-transgenic mice. Littermates were used as control. BAC GLT1 eGFP
transgenic mice were made as previously described (Regan et al., 2007). For
AAV8 injection, 2.5 ml virus (1012–13 genome particle/ml) particles mixed with
0.5 ml 0.2% fast green was injected by glass capillary micropipette into cere-
bral lateral ventricle of P0 pups of BAC GLT1 eGFP transgenic mice. Mice
were sacrificed three weeks after injection. For thoracic transection and ricin
administration, mice (8 weeks old) received i.p. injections of anesthetic cock-
tail (ketamine [95 mg/kg; Fort Dodge Animal Health; Fort Dodge, IA] and xyla-
zine [10 mg/kg; Bayer, Shawnee Mission, KS]). After anesthesia, a laminectomy
was performed above the T9 spinal cord level and the dura was excised above
the injury site using a 30-gauge needle. Microscissor cuts were made at both
the rostral and caudal extents of the T9 spinal cord level to remove the T9
segment, followed by gentle aspiration in the lesion cavity. A small piece of
Gelfoam was used to fill the lesion cavity. Postoperative care included
buprenorphine (Reckitt Benckiser; Richmond, VA), subcutaneous injection
of lactated ringers’ solution and twice-daily expression of bladders up to
7 days postinjury. For Ricin administration, femoral nerves on both sides
were exposed and transected. The nerves were then crushed about 15 mmproximal to transection and dipped into fluoro-ruby (FR, 10%) or mixture of
ricin (final concentration, 1 mg/ml) and FR(10%) solution for 60 min.
Image Quantification, Graphics, and Statistical Analysis
All quantitative analysis of images was performed in Image J by measuring the
intensity of signals. Data was plotted in PRISM (GraphPad Software, Inc) or
SigmaPlot (SPSS). Two-way and one-way ANOVA (Bonferroni post hoc anal-
ysis) along with Student’s t test were used for statistical analysis where appro-
priate (details, see figure legends) (JMP software, ver.7; SAS Inst. Cary, NC).
p values < 0.05 were considered significant employing a two-tailed analysis.
In some cases, quantification of gels was performed by Quantity One Software
(BioRad Inc. Hercules, CA).
SUPPLEMENTAL DATA
The Supplemental Data include six figures and one movie and can be
found with this article online at http://www.neuron.org/supplemental/S0896-
6273(09)00155-X.
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